(6Z,15Z)-11-((Z)-dec-4-en-1-yl)docosa-6,15-dien-10-yl (3-(dimethylamino)propyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (6Z,15Z)-11-((Z)-dec-4-en-1-yl)docosa-6,15-dien-10-yl (3-(dimethylamino)propyl)carbamate
• 英文别名: [(6Z,15Z)-11-[(Z)-dec-4-enyl]docosa-6,15-dien-10-yl] N-[3-(dimethylamino)propyl]carbamate
• 化学式: C₃₈H₇₂N₂O₂
• 分子量: 589.002
• InChiKey: WHSHLWUTCHSWDW-LKKYKVRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.5
• 重原子数：
  42
• 可旋转键数：
  31
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (6Z,15Z)-11-((Z)-dec-4-enyl)henicosa-6,15-dien-10-ol 在 吡啶 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成 (6Z,15Z)-11-((Z)-dec-4-en-1-yl)docosa-6,15-dien-10-yl (3-(dimethylamino)propyl)carbamate
  参考文献：
  名称：

  [EN] TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF
  [FR] LIPIDES CATIONIQUES TRIALKYLÉS ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明提供了用于将治疗剂传递给细胞的组合物和方法。具体包括新颖的三烷基阳离子脂质和核酸-脂质颗粒，这些颗粒能够有效地封装核酸并将封装的核酸有效地传递给体内的细胞。本发明的组合物非常有效，因此可以在相对较低的剂量下有效地降低特定靶蛋白的表达。

  公开号：

  WO2013126803A1

文献信息

• COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA
  申请人：PROTIVA BIOTHERAPEUTICS, INC.

  公开号：US20160151284A1

  公开（公告）日：2016-06-02

  The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.

  本发明提供了包含mRNA分子封装在脂质颗粒内的组合物。脂质颗粒包括一个阳离子脂质、一个非阳离子脂质和一个被封装在脂质颗粒内的mRNA分子。这些组合物可用于将mRNA分子引入人体受试者，从而产生一个多肽，其功能是改善一种或多种疾病症状。本发明还提供了用于制备上述组合物的阳离子脂质。
• TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF
  申请人：PROTIVA BIOTHERAPEUTICS, INC.

  公开号：US20150064242A1

  公开（公告）日：2015-03-05

  The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

  本发明提供了用于向细胞传递治疗剂的组合物和方法。特别地，这些包括新型的三烷基阳离子脂质和核酸-脂质颗粒，这些颗粒提供了核酸的高效封装和在体内有效地传递该封装的核酸到细胞的方法。本发明的组合物非常有效，因此在相对较低的剂量下允许有效地抑制特定靶蛋白。
• Trialkyl cationic lipids and methods of use thereof
  申请人：ARBUTUS BIOPHARMA CORPORATION

  公开号：US10561732B2

  公开（公告）日：2020-02-18

  The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

  本发明提供了向细胞输送治疗剂的组合物和方法。其中特别包括新型的三烷基阳离子脂质和核酸-脂质颗粒，它们能有效地封装核酸并将封装的核酸高效地输送到体内细胞。本发明的组合物具有很高的效力，因此能以相对较低的剂量有效地敲除特定的靶蛋白。
• NUCLEIC-ACID CONTAINING LIPID NANO-PARTICLE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210052646A1

  公开（公告）日：2021-02-25

  The present invention provides a lipid nanoparticle containing the following (a) to (c): (a) a nucleic acid encoding a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR); (b) a cationic lipid; and (c) a non-cationic lipid. The present invention also provides a CAR- or exogenous TCR-zo expressing immunocyte obtained by introducing the lipid nanoparticle into in vivo or ex vivo T cells, and an in vivo or ex vivo therapeutic approach using the immunocytes for disease such as cancer and the like.
• US9352042B2
  申请人：——

  公开号：US9352042B2

  公开（公告）日：2016-05-31